drugset / Trial / NCT01145170
Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma
Phase 2
Completed
40 enrolled
Eurofarma Laboratorios S.A.
Centro de Immunologia Molecular, Cuba · collab
NaSingle-groupOpen-labelTreatment
Summary
The study consists in only one treatment group, which will receive the first-line therapy for the disease - standard radiotherapy and a 150 mg/m2 dose of the investigational product (nimotuzumab)
Timeline
- Start
- 2011-03
- Primary completion
- 2014-06
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 150 mg/m2 | — |